Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
AIDS first emerged decades ago; however, its cure, i.e., eliminating all virus sources, is still unachievable. A critical burden of AIDS therapy is the evasive nature of HIV-1 in face of host immune responses, the so-called “latency.” Recently, a promising approach, the “Shock and Kill” strategy, wa...
Main Authors: | Thanarat Salahong, Christian Schwartz, Rungroch Sungthong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/6/1026 |
Similar Items
-
Brd/BET Proteins Influence the Genome-Wide Localization of the Kaposi’s Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus Major Latency Proteins
by: Rishikesh Lotke, et al.
Published: (2020-10-01) -
Relevance of BET Family Proteins in SARS-CoV-2 Infection
by: Nieves Lara-Ureña, et al.
Published: (2021-07-01) -
Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
by: Edrous Alamer, et al.
Published: (2021-01-01) -
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
by: John Hilton, et al.
Published: (2022-08-01) -
The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target
by: Ekaterina Flin, et al.
Published: (2017-05-01)